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The extravasation of cancer cells is a key step of the metastatic
cascade. Polymorphisms in genes encoding adhesion molecules
can facilitate metastasis by increasing the strength of interaction
between tumor and endothelial cells as well as impacting other
properties of cancer cells. We investigated the Ser128Arg (a561c
at the nucleotide level) polymorphism in the E-selectin gene in
patients with metastatic colon cancer and its functional signifi-
cance. Genotyping for a561c polymorphism was performed on 172
cancer patients and on an age-matched control population. The
colon cancer group was divided into groups with (M1) and with-
out observable metastasis (M2). For in vitro functional assays,
Huvec transfected cells expressing wild-type (WT) or the S128R
variant of E-selectin were established to study in vitro binding
ability and signal transduction processes of T84 colon cancer cell
line. Our results demonstrated that the Arginine128 allele was
more prevalent in the M1 group than in the M2 group or normal
controls (p < 0.005; odds ratio, 1.56; 95% confidence interval (CI)
1.16–1.92; p < 0.001, odds ratio 5 1.65; CI 5 1.24–1.99, respec-
tively). In vitro, S128R E-selectin transfected Huvec cells, sup-
ported increased adhesion as well as increased cellular signaling
of T84 cancer cells compared to WT E-selectin and mock-trans-
fected Huvec cells. These findings suggest that the E-selectin
S128R polymorphism can functionally affect tumor-endothelial
interactions as well as motility and signaling properties of neoplas-
tic cells that may modulate the metastatic phenotype.
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Metastasis is the main cause of death for cancer patients. Meta-
static dissemination is a complex process, depending on the ability
of malignant cells to escape from the primary tumor, penetrate
and flow through the bloodstream, adhere to the vascular bed and
then invade and proliferate in the organ parenchyma.1 Interactions
of blood-borne carcinoma cells and the microvasculature are
essential prerequisites for metastasis to occur. These processes
involve mechanical contact and transient attachment, which are
mediated by endothelial surface adhesion molecules and their
ligands on the neoplastic cells.2 Factors mediating these interac-
tions are therefore viewed as important determinants of the meta-
static phenotype. Among the molecules mediating tumor-endothe-
lium interactions are selectins.3–7 The selectins are a small family
of intercellular adhesion molecules with 3 members: E-, P- and L-
selectin. They share a mosaic structure consisting of an amino-ter-
minal domain followed by an epidermal growth factor (EGF)-like
domain, a variable number of complement regulatory repeats, a
transmembrane domain and a short cytoplasmic domain. E-selec-
tin (ELAM-1) is expressed by endothelial cells, which are acti-
vated by cytokines released during the inflammatory process and
plays an important role in neutrophil extravasation into injured tis-
sues as well as in neoplastic cell extravasation.8 A correlation
between the expression of E-selectin, the E-selectin ligands (i.e.,
sialyl-LewisX or sialyl-LewisA) with the metastatic potential of
malignant cells is best documented for colon carcinomas.9–12
Several findings regarding E-selectin polymorphisms have been
described.13,14 The S128R polymorphism (a substitution of an
uncharged serine with a positively charged arginine within the
EGF domain) is of interest for 2 reasons: first, it is overrepresented
in certain patient groups affected by disease characterized by an
increased adhesiveness of leukocytes to endothelium such as ath-
erosclerosis and myocardial infarction15,16 and second, it is a func-
tional polymorphism since it modifies ligand affinity.17 Since there
exists a mechanistic similarity between leukocyte and tumor-cell
extravasation, it is therefore reasonable to hypothesize that natu-
rally occurring E-selectin gene polymorphisms might underlie var-
iations observed between individuals in their susceptibility to me-
tastasis formation. However, the physiological importance of the
S128R polymorphism in the pathogenesis of metastasis has not
been explored yet.
In this study we have tested and affirmed the hypothesis that the
S128R polymorphism frequency is significantly higher in patients
with metastatic cancer compared to patients with localized disease
without metastasis and healthy normal controls. We also demon-
strate, through the use of an experimental model of Huvec cell
transfectants, expressing wild-type and the variant form of E-
Selectin, that this polymorphism is able to affect the adhesion and
motility of tumor cells as well as to functionally alter biochemical
pathways, which may modulate the overall metastatic phenotype.
Material and methods
Cell culture
T84 (ICLC, Genova, Italy) human colon cancer cells were
maintained in DMEM-F12 (BioWhittaker, Verviers, Belgium)
supplemented with 10% fetal calf serum (FCS) (BioWhittaker,
Verviers, Belgium), 100 U/ml penicillin and 100 lg/ml streptomy-
cin (Euroclone, UK). Human umbilical vein endothelial cells
(HUVEC) were obtained from Clonetics (Bio-Whittaker, Verviers,
Belgium) and grown according to supplier’s information. CHO
cells (ICLC, Genova, Italy) were grown in F12 Ham’s medium,
supplemented with 10% fetal calf serum, 100 U/ml penicillin and
100 lg/ml streptomycin. All cells were maintained at 37C under
5% CO2 atmosphere. All other reagents were purchased from
Sigma (St. Louis, MO), if not otherwise cited.
E-selectin genotyping and statistical analysis
The study involved 172 Caucasian patients with histologically
confirmed diagnosis of colon cancer who were referred for treat-
ment to the Oncology Unit at the University Hospital of Palermo,
Italy. No subjects with a family history of early onset colon cancer
or multiple cancer cases were included into the study. Metastasis
were located in different organ sites and their distribution was in
line with patterns observed in developed Western countries.18 Age
of patients at diagnosis ranged from 57 to 85 (median, 64 years).
Stage grouping is indicated in accordance with the guidelines of
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International Union Against Cancer. The characteristics of cancer
patient and their tumors are reported in Table I.
A group of 80 age-matched Caucasians with no history of can-
cer, most of them blood donors, was recruited as control group.
Informed consent was obtained from all participants. DNA was
extracted from paraffin-embedded tumor tissue or from peripheral
blood using a commercially available kit (QIAAmp, Qiagen, Hil-
den, Germany). To determine the distribution of E-Selectin Ser-
ine128 and Arginine128 alleles in metastatic colon cancer patients
and in control groups, the following primers were used: 50-AAA
ATC AAA GGC ACT CAG TAT AAG CA-30 (in the forward
direction) and 50-GAA CGT GAG ATG GTG CTA CCA-30 (in
the reverse direction). PCR amplification was performed in a final
volume of 30 ll containing 200 ng of DNA, 1.5 mM MgCl2,
10 mM Tris–HCl (pH 8.3), 50 mM KCl and 0.2 mM each of
dCTP, dATP, dTTP and dGTP (Amersham Pharmacia, Uppsala
Sweden), each primer at 1.0 lM and 1 U of Taq polymerase
(Amersham Pharmacia, Uppsala, Sweden) in a 9700 Applied Bio-
system Thermocycler. PCR products (229 bp) were visualized on
2% agarose gels with 10% ethidium bromide. The A to C transver-
sion (a561c) abolishes a PstI restriction enzyme site, therefore
genotyping was performed by PCR-RFLP with this enzyme.16
Subsequent confirmation of variants was performed by direct
sequencing. Differences between groups were examined by v2
test. The association of E-Selectin genotypes with the risk of me-
tastasis was examined in terms of odds ratio (OR) and 95% confi-
dence intervals (CIs). For each OR, two-tailed probability values
were calculated. All statistical analyses were done using SPSS
version 10.0 (Chicago, IL). p < 0.05 was assumed to be statisti-
cally significant. Because of their small number, E-Selectin Argi-
nine128 homozygotes were grouped together for analysis with het-
erozygotes and treated as carriers for analysis.
Vector construction, transfection and isolation of
stable transfectants
Human wild-type E-selectin cDNA cloned in the expression
vector pMT2 was a gift from Dr. G. Kansas.19 The A to C trans-
version in cDNA position 561 was generated by QuikChange1 II
Site-Directed Mutagenesis Kits (Stratagene, La Jolla, CA) using
primers a561c Forward (50-CCAATACATCCTGCCGTGGC-
CACGGTGAAT-30) and a561c Reverse (50-ATTCACCGTGGC-
CACGGCAGGATGTATTGG-30); procedure was made according
to manufacturer’s protocol. All mutant constructs were verified by
sequencing in both orientations using the ABI Prism Big Dye Ter-
minator Cycle Sequencing Ready Reaction Kit (vers. 1.1) and the
ABI 310 Genetic Analyzer (Applied Biosystems, Foster City,
CA).
Huvec were transfected in transient with wild-type (Huvec-ES-
WT), S128R E-Selectin (Huvec-ES-S128R) or empty plasmid
using jetPEITM-HUVEC transfection kit (Polyplus-transfection,
San Marcos, CA) according to the manufacture’s instructions.
Briefly, HUVEC were seeded at 3.5 3 104 cells/well in a 24-well
plate previously coated with collagen type I (Sigma, St. Louis,
MO) and grown to 60–70% confluence. For transfection, 2 lg
plasmid DNA was diluted in 50 ll of 150 mM NaCl solution and
mixed with 50 ll of 150 mM NaCl solution containing 4 ll of
polymer complexes of jetPEI-HUVEC DNA transfection reagent.
After 30 min of incubation, the mixture was added dropwise onto
the well and homogenized by gently swirling the plate. The plate
was incubated at 37C and 5% CO2 in a humidified atmosphere
for 4 hr and thereafter medium was replaced with HUVEC growth
medium.
In some set of experiments Chinese hamster ovary (CHO) cells
engineered to express wild-type or polymorphic E-selectin were
used. For this purpose, CHO were stable transfected with wild-
type (CHO-ES-WT), S128R E-Selectin (CHO-ES-S128R) or
empty plasmid using LipofectAMINE 2000 (Invitrogen Corpora-
tion, Carlsbad, CA). Briefly, CHO cells were plated onto 12-well
tissue culture plates (CoStar, Cambridge, MA) and grown to 70–
80% confluence. Each well was inoculated with 500 ll of Opti-
MEM (InVitrogen Life Technologies, Carlsbad, CA) containing
LipofectAMINE 2000 at 8 lg/ml and the vector constructs at 2
lg/ml for 4 hr. Cells were further incubated overnight with the
addition of 500 ll/well of regular CHO medium consisting of a-
minimal essential medium (MEM) supplemented with 10% fetal
calf serum and 2 mM l-glutamine, washed and replaced with CHO
medium. Successfully transfected cells were selected by the addi-
tion of 3 lg/ml of puromycin.
Conditioned medium
CHO-ES-WT, CHO-ES-S128R and mock-transfected cells
were grown to confluence, washed several times in PBS and then
incubated with serum-free medium for 48 hr. The conditioned me-
dium (CM) was centrifuged at low speed to remove cell debris
and then stored at 280C until used for motility and invasion
assays.
Cell-binding assays to E-selectin expressing Huvec
HUVEC-ES-WT, HUVEC-ES-S128R cells and mock-trans-
fected cells were grown to confluence in 24-well tissue culture
plates. HUVEC cells were fixed as previously described.9 Briefly
cells were fixed with glutaraldehyde 0.0125% (Agar Scientific,
Stanted, Essex, UK) and then treated with 10 mM ethanolamine to
block free aldehydic groups and washed several times before plat-
ing the cancer cells. T84 cells were detached with 10 mM PBS/
EDTA, resuspended at 303 104 cells/ml in plain medium contain-
ing 0.5% BSA and allowed to attach for 15 min on the fixed
HUVEC monolayer. After this, gentle washing was performed
with PBS and 300-ll fresh medium was added into each well.
Forty microliters of a 5 mg/ml stock solution of MTT was added
to the cells, followed by an incubation at 37C for 5 hr. After this
period, the supernatants were decanted and 300 ll of 100%
DMSO was added. Stained products were released from the cells
after shaking for 10 min. Cell absorbance was measured at 550 nm
with a spectrophotometric plate reader (Bio-Tek Instruments,
Winooski, VT). For inhibition experiments, a monoclonal anti-
body against E-selectin (1.2B6, Santa Cruz Biotechnology, Santa
Cruz, CA) or a control antibody of the same isotype (Santa Cruz
TABLE I – CLINICAL CHARACTERISTICS OF COLON
CANCER PATIENTS AND CONTROLS
Cancer patients Controls
n5 172 n5 80
n (%) n (%)
Median (range) age 64 50
Sex
Male 100 (39.7) 30 (37.5)
Female 152 (60.3) 50 (62.5)
Lymph node status
pN0 84 (48.9)
pN1 88 (51.1)
Metastasis at diagnosis
Presence (M1) 90 (52.4)
Absence (M2) 82 (47.6)
Tumor location
Caecum 22 (12.7)
Ascending colon 14 (8.4)
Transverse colon 15 (8.7)
Descending colon 18 (10.7)
Sigmoid colon 43 (25)
Rectum 60 (34.5)
Tumor size (cm)
<5 70 (40.6)
>5 102 (59.4)
UICC stage
I 54 (31)
II 30 (17.5)
III 62 (36)
IV 26 (15.5)
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Biotechnology, Santa Cruz, CA) was preincubated with the
HUVEC monolayer at 2 lg/well for 1 hr prior to the adhesion
assays.
Migration assay
Tumor-cell motility was studied using a 48-well chemotaxis
chamber (Neuroprobe, Cabin John, MD) with a gelatin-coated
polycarbonate filter (12 lM pore size). About 2 3 106 cells/ml
were placed in the top wells and incubated for 16 hr. CM from
transfectants was added in the bottom wells. At the end of assay,
filters were removed and the membranes fixed and then stained
with Diff-Quick. Each test group was assayed in quadruplicate.
Five high-power (4003) fields were counted and the results were
expressed as number of cell present/high power field.
As indicated, a monoclonal antibody against E-selectin or a
control antibody of the same isotype was added at 2 lg/ml in the
bottom well with the CM and migration quantified as mentioned
earlier.
Western blot
Mock- and E-selectin-transfected HUVEC cells were grown
and fixed as mentioned earlier. T84 cells were added to the
HUVEC monolayer. Adherent cells were recovered and lysed in
buffer (300 mM NaCl, 50 mM Tris–HCl pH 7.6, 0.1% Triton,
1 mM PMSF, 10 lg/ml Leupeptin, 10 lg/ml Aprotinin, 4 mM
EDTA, 2 mM sodium orthovanadate, 10 mM PPI and 100 mM
NaF) on ice for 1 hr. The lysates were clarified at high speed
centrifugation for 150 and an aliquot of the supernatant was
assayed to determine protein concentration. Equal amounts of
proteins were separated by a 6% SDS-polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membrane (Protran
Schleicher&Schuell, Germany). The membrane was incubated in
block solution (1 M glycine, 1.25% dry milk and 0.1% ovalbu-
mine), and probed overnight with antiphosphotyrosine antibody
(PY20; Santa Cruz Biotechnology, CA). After 3 washes with WS
the membrane was incubated with horseradish peroxidase-conju-
gated secondary antibody and proteins were detected by the
enhanced chemiluminescence detection system (Super Signal,
Pierce, Rockford, IL). The blots were stripped and reprobed with
antiactin antibodies (Cell Signaling Technology, Beverly, MA) to
ensure equal loading and transfer of proteins. For p44/42 MAP
kinase (ERK 1/2) and phospho-p44/42 MAP kinase (p-ERK 1/2)
protein level evaluation the cell lysates were separated by SDS-
polyacrylamide gel electrophoresis, transferred to nitrocellulose
membrane and then the membrane was probed overnight at 4C
with specific antibodies against ERK 1/2 (Cell Signaling Tech-
nology, Beverly, MA) and p-ERK 1/2 (Cell Signaling Technol-
ogy, Beverly, MA), respectively. Proteins corresponding to ERK
1/2 and p-ERK 1/2 were identified by using the detection proto-
col mentioned earlier.
Immunofluorescence
T84 cells were plated at 3 3 105 cells/well on a confluent
mock- and E-selectin-transfected fixed CHO monolayer. After
3 hr, cells were washed with PBS, fixed in 3.7% paraformaldehyde
for 100, permeabilized for 50 with 0.5% Triton X-100 and blocked
in 1% BSA for 600. Cells were incubated with an antiphosphotyro-
sine antibody for 600 at 37C, washed 3 times with PBS and then
incubated with the fluorescein-conjugated secondary antibody for
600. After several washes, coverslips were mounted in moviol and
viewed by fluorescence microscopy (Olympus BX50). For the
quantification of total levels of phosphotyrosine images were
taken from 10 different fields with identical acquisition parame-
ters, and the mean of intensity was measured using photoshop 7.0
software (Adobe), values were background-corrected by regions
outside the cells.
Results
Distribution of genotypes
Of 90 metastatic colon cancer patients tested, 63 (70%) were
homozygous for the E-Selectin Serine128 allele, 23 (25.6%) were
heterozygous S128R and 4 (4.4%) were homozygous for the Argi-
nine128 allele. Concerning the 82 nonmetastatic colon cancer
patients, 72 (87.8%) were homozygous for the E-Selectin Ser-
ine128 allele, 8 (9.8%) were heterozygous S128R and 2 (2.4%)
were homozygous for the Arginine128 allele. For both categories,
the homozygous Arginine 128 genotypes were not analyzed sepa-
rately because of insufficient power but were grouped with the
heterozygotes for statistical analyses. The genotypic distribution
of the wild-type E-selectin allele in healthy controls was found
similar to values observed in previous studies in Caucasian popu-
lation.15,20
As shown in Table II, there was a statistically significant corre-
lation between the E-selectin Arginine128 allele and the M1 sub-
group vs. controls (p 5 0.001, OR 5 1.65; CI 5 1.24–1.99) and
vs. M2 subgroup (p 5 0.005, OR 5 1.56; CI 5 1.16–1.92) indi-
cating an association between the polymorphic allele and cancer
progression. The frequency of a561c allele showed no statistical
difference between M-patients and controls (p5 0.657).
Expression of S128R E-selectin in HUVEC modulates colon
cancer cell adhesion and motility
The effect of expression of E-selectin wild-type and the a561c
polymorphic allele was evaluated in transfected HUVEC cells
with the aim to investigate the role of this naturally occurring
polymorphism on cancer cell adhesion and motility. We have pre-
viously demonstrated that T84 colon carcinoma cells are endowed
with the proper surface receptors to recognize and adhere to E-
selectin.21,22 Figure 1a shows that HUVEC-ES-S128R cells sup-
port significantly greater levels of T84 cell adhesion than
HUVEC-ES-WT and mock-transfected HUVEC cells. Signifi-
cantly, the percentage of adhesion of cancer cells to HUVEC-ES-
WT was comparable to that achieved when T84 cells are plated on
TNF-a stimulated endothelial cells.9 To confirm that the attach-
ment of colon cancer cells was mediated by E-selectin, we used
the E-selectin blocking monoclonal antibody (1.2B6) in our adhe-
sion assay; pretreatment of transfectants HUVEC cells with 1.2B6
antibody significantly inhibited T84 cell adhesion compared to
mock-transfected cells (p < 0.05). Similar results were obtained
using E-selectin transfected CHO cells (data not shown).
Studies have demonstrated that a soluble isoform of E-selectin
(sE-selectin) is rapidly shed from the cellular surfaces and that it
acts as a monocyte chemotactic agent.23,24 To examine the hy-
pothesis that sE-selectin might stimulate motility of cancer cells,
CM from CHO transfectants was used in Boyden chamber chemo-
taxis assays. CM was prepared from CHO-transfected cells since
primary endothelial cells are sensitive to serum-free condition.
CM from CHO-ES-S128R cells induced T84 cells chemotaxis at
significantly higher levels when compared with CM from CHO-
ES-WT- (1.7-fold increase) and mock-transfected cells (2.5-fold
increase) (Fig. 1b). To demonstrate the involvement of sE-selectin
in T84-stimulated motility, CM was added to the Boyden chamber
in the presence of 1.2B6 anti E-selectin antibody. The incubation
of CM with the antibody decreased cancer cells chemotaxis when
compared with the effects mediated by isotype control antibody
TABLE II – E-SELECTIN GENOTYPES IN PATIENTS AND CONTROLS
Genotype
Controls
Nonmetastatic
(M2)
Metastatic
(M1)
No. % No. % No. %
aa 72 90 72 87.8 63 70
ac 1 cc 8 10 10 12.2 27 30
c allele frequency 0.05 0.09 0.175
M1 vs. healthy controls p 5 0.001; M1 vs. M2 5 0.005; M2 vs.
healthy controls p5 0.657.
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(p < 0.05). Data are representative of 3 independent experiments
each done in quadruplicate.
Modulation of signaling pathways in colon cancer cells adhering
to S128R transfected HUVEC cells
To explore a functional consequence of the S128R polymor-
phism in E-Selectin-stimulated signaling, IP/Western blot analyses
were carried out using lysates prepared from T84 colon cancer
cells after adhesion to HUVEC-ES-S128R, HUVEC-ES-WT cells
and mock-transfected HUVEC cells. As a marker for signal trans-
duction, we initially looked at cellular tyrosine phosphorylation;
immunoprecipitation/western blot analyses with a monoclonal
antibody that specifically recognize phosphorylated tyrosine resi-
dues allowed to detect changes in global cellular tyrosine phos-
phorylation. As shown in Figure 2a (upper panel), adhesion of co-
lon cancer cells to HUVEC-ES-WT cells caused an increase in ty-
rosine phosphorylation of proteins corresponding approximately
to molecular sizes of 45, 60, 85, 120 and 180 kDa compared to the
adhesion of tumor cells to mock-transfected HUVEC cells. Tyro-
sine phosphorylation signaling was further increased in T84 cells
adhering to HUVEC-ES-S128R cells suggesting that this polymor-
phism may affect E-selectin ligand-mediated signal transduction
in cancer cells. This conclusion was also strengthened by the evi-
dence that the addition of a neutralizing anti-E-selectin antibody
resulted in a pronounced reduction of tyrosine phosphorylation
levels in T84 adhered to transfected Huvec cells. To determine
whether another key signaling pathway was activated, whole cell
extracts were prepared and immunoblotted with antibodies specifi-
cally recognizing the phosphorylated and active forms of ERK1/2.
As shown in Figure 2b (upper panel), adhesion of cancer cells to
CHO-ES-WT cells activated the phosphorylation of ERK1/2 2-
fold increase) as detected by phosphospecific antibodies against
ERK1/2, whereas total ERK proteins remained unchanged (bottom
panel). ERK 1/2 phosphorylation was strongly increased following
adhesion of T84 cells to CHO-ES-S128R cells (2.5-fold increase).
To further confirm our biochemical results, E-Selectin-induced
tyrosine phosphorylation was evaluated by immunofluorescence in
cancer cells adhered to transfectants CHO cells. Figure 3 and Ta-
ble III show an increase in immunostaining of T84 cells (arrows)
plated on CHO-ES-S128R cells (c) that accompanies cancer cell
spreading after 3 hr from seeding compared to intensity of fluores-
cence of tumor cells plated on CHO-ES-WT (b) and mock-trans-
fected cells (a).
Discussion
Several reports in the last few years have indicated that besides
the imbalance in regulatory pathways because of activation of
oncogenes or loss of tumor suppressor genes, cancer progression
and clinical outcomes may be greatly modulated by functional
alteration in key proteins often determined by genetic polymor-
phisms.25–27 Accordingly, our study found that a single nucleotide
polymorphism in E-selectin gene is significantly associated with
the presence of metastases in colon carcinoma patients suggesting
a link between genetic host background and tumor-endothelial cell
interaction.
Adhesion of circulating cancer cells with vascular endothelium
is critical during early stages of the metastatic process.1 Data
strongly suggest that E-selectin expression on activated endothe-
lium may facilitate cancer cell seeding.28–30 Our hypothesis was
that a functional polymorphism (associated with a variation in the
structure and ligand affinity of the molecule) affecting E-selectin
could influence cancer cell biological behavior and colon cancer
risk. The Ser128Arg polymorphism in the E-selectin gene has
been associated with a higher risk of severe atherosclerosis,15
myocardial infarction,31 ischemic cerebrovascular disease,32
enhanced coagulation and systemic lupus erythematosus20,33,34;
pathologies where increased leukocyte-endothelial cells interac-
tion are observed. From a biological point of view, this specific
polymorphism has been demonstrated to exert a significant effect
on ligand recognition and binding, as cell transfectants expressing
the a561c E-selectin allele better support interactions with leuko-
cytes under shear flow conditions.35
FIGURE 1 – Functional assays of T84 cells on Huvec cells transfected with E-selectin Arg128 or Ser128 cDNA. (a) Adhesion of T84 cells to a
monolayer of Huvec cells expressing WT, S128R E-selectin or mock vector. Plating of cancer cells on Huvec-ES-S128R monolayer resulted in
a 2-fold increase of adhesion compared to cell attachment on Huvec-ES-WT monolayer. Treatment of Huvec monolayer with anti-E-selectin
antibody caused a 20% inhibition of cell attachment. A matched isotype antibody used as control does not exert any effect on cell adhesion (* 5
p < 0.05; ** 5 p < 0.01, when comparing two groups as indicated). (b) Stimulation of cancer cell motility by CM of transfectants CHO. CM
from CHO-ES-S128R stimulates a higher T84 chemotaxis with respect to cell motility induced by medium from CHO-ES-WT cells (1.7-fold
increase). Addition of anti-E-selectin antibody to CM of CHO cells inhibited the directional migration of the cells in response to CM (** 5 p <
0.01, when comparing 2 groups as indicated). Results presented are representative of n5 3 experiments, each one done in quadruplicate.
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Colorectal cancer (CRC) is one of the leading causes of mortal-
ity and accounts for 200,000 deaths per year in Europe and
USA.36 CRC is probably the type of cancer for which the most is
known about the genes affected by somatic mutations, their nor-
mal functions and their carcinogenic effects when mutated; lim-
ited evidence is available about the influence of genetic polymor-
phisms on clinical outcome, most of the studies have been focused
on genes encoding for metabolism enzymes as well as genes
encoding DNA synthesis and repair enzymes.37 Selectins have
been shown to play a critical role in tumor cell-endothelial cell
interaction in CRC.38 No evidences have been produced on the
role of the S128R polymorphism of E-selectin in cancer and more
specifically in colon cancer. Our results suggest, for the first time
to our knowledge, that individuals carrying the 128R allele of the
E-selectin may present a higher risk, once they develop a tumor,
to metastasis formation. The identification of new molecular
markers of more aggressive colonic cancer phenotypes may in
principle to individually tailor therapy to improve clinical out-
come. These findings, whereas relevant, are preliminary. The
small sample size requires to widen the screen and to include a
higher number of patients. Furthermore, since metastasis forma-
tion depends by a number of adhesion molecules, any single muta-
tion will only provide a small or modest contribution to the overall
risk.
To correlate the increased colon metastasis risk with a func-
tional role of this specific E-selectin polymorphism, we investi-
gated if the expression in vitro of this variant form of E-selectin
could amplify the adhesiveness of neoplastic cells to endothelial
cells as well as alter downstream phosphorylation events. To
examine this issue, we created an experimental model that used
Huvec cells that were engineered to express wild-type E-selectin
or S128R variant E-selectin. We found that S128R polymorphism
of E-selectin significantly enhanced the adhesion of T84 colon
cancer cells compared to WT E-selectin and mock vector.
The involvement of E-selectin in the adhesion of T84 colon
cancer cells to Huvec monolayer was supported by the observation
that pretreating Huvec cells with an anti-E-selectin neutralizing
antibody, but not with a matched isotype antibody, inhibited the
adhesion of tumor cells. The incomplete inhibition of adhesion by
the neutralizing antibody can be explained with the presence of
other adhesion molecules on endothelial cell surface affecting the
attachment of T84 cells on Huvec.
Data in the literature have demonstrated that the ability of colon
cancer cells to bind to E-selectin expressed on activated endothe-
lial cells is directly proportional to their metastatic potential.39
Although a stronger adhesion of cancer cells to the endothelial
cell surface should theoretically compromise their ability to move
and migrate in the target organ, it is noteworthy to observe that
evidence of the last years has demonstrated that surviving meta-
static cells proliferate intravascularly after adhesion to the endo-
thelium, and extravasation of the tumor occurs when intravascular
micrometastatic foci outgrow the vessels they are in.40,41
In this framework our findings that S128R variant form of E-
selectin determines an increased adhesion of neoplastic cells com-
pared to the wild-type allele add a new level of investigations to
the role of selectins in metastatic process.
Transendothelial migration by tumor cells requires a coordi-
nated series of steps including: cancer attachment to the endo-
thelial cell surface, modifications of the cytoskeletal organiza-
tion, detachment from the substrate and active migration into
the host connective tissue. The ability of cancer cells to respond
to a variety of chemoattractant molecules in an autocrine and/or
paracrine manner is well known; several growth factors as well
FIGURE 2 – Activation of cell signaling in T84 colon cancer cells after adhesion to transfectants Huvec cells. (a) Immunoprecipitation/western
blot analysis for cell lysates from T84 cells plated on different transfectants Huvec cells showing a clear difference in the pattern of basal tyro-
sine phosphorylation (upper panel). Pounceau staining of the membrane is shown to ensure equal loading and transfer of proteins (bottom panel);
(b) Addition of T84 cells to transfectants CHO is associated with increased phosphorylation of ERK 1/2. After adhesion to CHO cells, T84 can-
cer cells were harvested, and the whole cell extracts were separated on a 12% SDS-PAGE gel. The blots were probed with antibodies against
phospho-specific ERK1/2 (upper panel) or nonphosphorylated ERK1/2 as indicated. These blots are representative of 3 independent experi-
ments. Total ERK in these experiments also serves as control for loading and transfer of proteins. Columns, mean densitometer quantification of
the fold stimulation values relative to the control culture; bars, SD. *p < 0.05; **p < 0.005 (bottom panel).
532 ALESSANDRO ET AL.
as extracellular matrix components have been shown to stimu-
late tumor cells chemotaxis and haptotaxis.42 The role of selec-
tins as chemoattractants for nonimmune cells has not been well
studied. P-selectin has been shown to induce endothelial cell
motility43 while E-Selectin was recently demonstrated to
enhance motogenic potential of HT-29 cells by activation of
stress-activated protein kinase and ERK pathways.6,44 To exam-
ine the hypothesis that the shed extracellular domain of poly-
morphic E-selectin might play a role in T84 cell motility, we
performed a series of chemotaxis assays in the Boyden chamber
system using the CM of transfectants CHO cells as the chemo-
attractant. We found that CM from S128R E-selectin-expressing
CHO cells possesses a higher chemotactic activity compared to
CM from WT E-selectin-expressing CHO cells and mock-trans-
fected CHO cell controls. The incubation of the CM with an
anti-E-selectin antibody significantly decreased cancer cell che-
motaxis when compared to incubation with an isotype control
antibody indicating that sE-selectin contributes to the CM che-
motactic activity for tumor cells.
The evidence that E-Selectin can induce chemotaxis in cancer
cells appears relevant for formation of metastases. Serum E-Selec-
tin levels are known to be elevated in patients with various can-
cers, reflecting the enhanced expression of E-Selectin in the vessel
walls of these patients.45,46 The circulating soluble E-Selectin may
thus not only be a sign of the augmented release of this molecule
from the endothelium but also may provide a soluble stimulant of
motility to direct cancer cells to the target organ.
Different studies have shown that intact, transmembrane E-
selectin can transduce signals in endothelial cells during leuko-
cyte recruitment.47,48 Little information has been gathered
regarding the signal transduction pathways activated by interac-
tion of E-selectin with the counter-receptor. Kumar et al. showed
that soluble E-selectin mediates monocytes recruitment through
the activation of Src-MAPK pathway.24 Koch and coworkers
have reported that soluble E-selectin induces angiogenesis in vivo
and stimulates in vitro the motility and tube formation of human
dermal microvascular endothelial cells through Src- and phospha-
tidylinositol 3-kinase-mediated pathways.49 In cancer cells, the
interaction of HT-29 colon carcinoma cells with TNFa-treated
FIGURE 3 – Immunolocalization of tyrosine-phosphorylated proteins in T84 colon carcinoma cells after adhesion to transfectants CHO. Adhe-
sion of T84 cells (arrows) to CHO-ES-S128R monolayer (c) resulted in an increase of cytoplasmic and nuclear staining for phosphotyrosine
compared to immunostaining observed for the cells adhering to CHO-ES-WT (b) and mock-transfected CHO cells (a). In Table III, it is indi-
cated as percent (%) of increase, the quantification of fluorescence intensities in the different samples. Cells were stained with PY20 and FITC-
conjugated secondary antibody as described in Materials and methods section. Adhering T84 colon carcinoma cells are indicated with white
arrows.
TABLE III – QUANTIFICATION OF FLUORESCENCE INTENSITIES IN T84
ADHERING TO TRANSFECTED CHO CELLS
Cell type Fluorescence increase in %
Mock-transfected CHO 100
CHO-ES-WT 146 (611)
CHO-ES-S128R 163 (617)
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HUVEC cells activates the MAPK SAPK2/p38 pathway leading
to transendothelial migration.44,50 We previously demonstrated
that the addition of E-selectin to colon cancer cells produces a 2-
fold increase in [Ca21]i that affects cytoskeleton reorganization,
cancer cell motility and tyrosine phosphorylation events in the
cells.21 Our present results, while confirming the activation of
signaling pathways in cancer cells stimulated by binding of E-
selectin, show that S128R polymorphism causes an increase in
tyrosine phosphorylation-mediated pathways and ERK 1/2 signal-
ing compared to WT E-selectin- and mock-transfected CHO
cells.
Angiogenesis is critical in the development of tumors, recent
data have demonstrated that sE-selectin is a potent angiogenic me-
diator, acting predominantly through the Src-PI3K pathway24,49; it
will be interesting to test whether polymorphic E-selectin is able
to modulate the formation of blood vessels thus to affect the meta-
static process also through revascularization.
In conclusion, our study, although needs to be validated in a
larger cohort, suggests that the presence of the E-selectin Arg128
allele may be a facilitating factor for cancer metastasis in colon
cancer patients.
Acknowledgements
We thank Prof. J. Medin for critical comments, Dr. M. Milazzo
for help in the statistical analysis, Dr G. Kansas for E-selectin
cDNA, Dr. Monica D’Amato for CHO-ES-WT cell preparation
and Prof. D. Lio for healthy controls DNA. F.D and C.C are PhD
students in Immunopharmacology at the Universita` of Palermo.
This work was supported by Italian Association for Cancer
Research (AIRC) to R.A. and G.D.L., Universita` di Palermo
(International Cooperation) to R.A. and A.M.F.; ex 60 % MURST
to R.A., A.M.F. and to G.D.L.
References
1. Chambers AF, Groom AC, MacDonald IC. Metastasis: dissemination
and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;
2:563–72.
2. Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM. Interac-
tions between cancer cells and the endothelium in metastasis. J Pathol
2000;190:310–29.
3. Krause T, Turner G. Are selectins involved in metastasis? Clin Exp
Metastasis 1999;17:183–92.
4. Burdick M, McCaffery J, Kim Y, Bochner B, Konstantopoulos K. Co-
lon carcinoma cell glycolipids, integrins, and other glycoproteins
mediate adhesion to HUVECs under flow. Am J Physiol Cell Physiol
2003;284:C977–87.
5. Kim Y, Borsig L, Han H, Varki N, Varki A. Distinct selectin ligands
on colon carcinoma mucins can mediate pathological interactions
among platelets, leukocytes, and endothelium. Am J Pathol 1999;155:
461–72.
6. Laferriere J, Houle F, Huot J. Regulation of the metastatic process by
E-selectin and stress-activated protein kinase-2/p38. Ann NY Acad
Sci 2002;973:562–72.
7. Voura E, Sandig M, Siu C. Cell-cell interactions during transendothe-
lial migration of tumor cells. Microsc Res Tech 1998;43:265–75.
8. Bird M, Foster M, Priest R, Malhotra R. Selectins: physiological and
pathophysiological roles. Biochem Soc Trans 1997;25:1199–206.
9. Alessandro R, Flugy A, Russo D, Stassi G, De Leo A, Corrado C,
Alaimo G, De Leo G. Identification and phenotypic characterization
of a subpopulation of T84 human colon cancer cells, after selection
on activated endothelial cells. J Cell Physiol 2005;203:261–72.
10. Brodt P, Fallavollita L, Wolitzky B, Labow M. E-selectin is involved
in liver colonization by metastatic carcinoma cells. Clin Exp Metasta-
sis 1996;14:74–5.
11. Wittig B, Kaulen H, Thees R, Schmitt C, Knolle P, Stock J, Meyer
Zum Bueschenfelde K, Dippold W. Elevated serum E-selectin in
patients with liver metastases of colorectal cancer. Eur J Cancer 1996;
7:1215–18.
12. Yamada N, Chung Y, Takatsuka S, Arimoto Y, Sawada T, Dohi T,
Sawa M. Increased sialyl Lewix A expression and fucosyltransferase
activity with aquisitation of a high metastatic capacity in a colon can-
cer cell line. Br J Cancer 1997;76:582–4.
13. Iida A, Nakamura Y. High-resolution SNP map in the 55-kb region
containing the selectin gene family on chromosome 1q24-q25. J Hum
Genet 2003;48:150–4.
14. Vora D, Rosenbloom C, Beaudet A, Cottingham R. Polymorphisms
and linkage analysis for ICAM-1 and the selectin gene cluster.
Genomics 1994;21:473–7.
15. Wenzel K, Felix S, Kleber F, Brachold R, Menke T, Schattke S,
Schulte K, Glaser C, Rohde K, Baumann G, Speer A. E-selectin poly-
morphism and atherosclerosis: an association study. Hum Mol Genet
1994;3:1935–7.
16. Ye S, Usher D, Virgil D, Zhang L, Yochim S, Gupta R. A PstI poly-
morphism detects the mutation of serine128 to arginine in CD 62E
gene—a risk factor for coronary artery disease. J Biomed Sci 1999;
6:18–21.
17. Revelle B, Scott D, Beck P. Single amino acid residues in the E- and
P-selectin epidermal growth factor domains can determine carbohy-
drate binding specificity. J Biol Chem 1996;271:16160–70.
18. Winawer S, Fletcher R, Miller L, Godlee F, Stolar M, Mulrow C,
Woolf S, Glick S, Ganiats T, Bond J, Rosen L, Zapka J, et al. Colorec-
tal cancer screening: clinical guidelines and rationale. Gastroenterol-
ogy 1997;112:594–642.
19. Kansas G, Pavalko F. The cytoplasmic domains of E- and P-selectin
do not constitutively interact with alpha-actinin and are not essential
for leukocyte adhesion. J Immunol 1996;157:321–5.
20. Hajeer A, El-Magadmi M, Alansari A, Bruce I E-selectin is a suscep-
tibility gene for systemic lupus erythematosus (SLE). Arthritis Rheum
2000;43:S362.
21. D’Amato M, Flugy AM, Alaimo G, Bauder B, Kohn EC, De Leo G,
Alessandro R. Role of calcium in E-selectin induced phenotype of
T84 colon carcinoma cells. Biochem. Biophys Res Commun 2003;
301:907–14.
22. Flugy AM, D’Amato M, Russo D, Di Bella MA, Alaimo G, Kohn EC,
De Leo G, Alessandro R. E-selectin modulates the malignant proper-
ties of T84 colon carcinoma cells. Biochem Biophys Res Commun
2002;293:1099–106.
23. Blann A, Seigneur M. Soluble markers of endothelial cell function.
Clin Hemorheol Microcirc 1997;17:3–11.
24. Kumar P, Hosaka S, Koch A. Soluble E-selectin induces monocyte
chemotaxis through Src family tyrosine kinases. J Biol Chem
2001;276:21039–45.
25. Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N, Bargonetti J,
Bartel F, Taubert H, Wuerl P, Onel K, Yip L, et al. A single nucleo-
tide polymorphism in the MDM2 promoter attenuates the p53 tumor
suppressor pathway and accelerates tumor formation in human. Cell
2004;119:591–602.
26. Bond G, Hu W, Levine A. A single nucleotide polymorphism in the
MDM2 gene: from a molecular and cellular explanation to clinical
effect. Cancer Res 2005;65:5481–4.
27. Houlston R, Peto J. The search for low-penetrance cancer susceptibil-
ity alleles. Oncogene 2004;23:6471–6.
28. Belanger S, St-Pierre Y. Role of selectins in the triggering, growth,
and dissemination of T-lymphoma cells: implication of L-selectin in
the growth of thymic lymphoma. Blood 2005;105:4800–6.
29. Biancone L, Arak iM, Araki K, Vassalli P, Stamenkovic I. Redirec-
tion of tumor metastasis by expression of E-selectin in vivo. J Exp
Med 1996;183:581–7.
30. Borsig L, Wong R, Hynes R, Varki N, Varki A. Synergistic effects of
L- and P-selectin in facilitating tumor metastasis can involve non-
mucin ligands and implicate leukocytes as enhancers of metastasis.
Proc Natl Acad Sci USA 2002;99:2193–8.
31. Yoshida M, Takano Y, Sasaoka T, Izumi T, Kimura A. E-selectin
polymorphism associated with myocardial infarction causes enhanced
leukocyte-endothelial interactions under flow conditions. Arterioscler
Thromb Vasc Biol 2003;23:783–8.
32. Hattori H, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K,
Suzuki N. A561C polymorphism of E-selectin is associated with ische-
mic cerebrovascular disease in the Japanese population without diabetes
mellitus and hypercholesterolemia. Brain Res 2006;1108:221–3.
33. Jilma B, Marsik C, Kovar F, Wagner O, Jilma-Stohlawetz P, Endler
G. The single nucleotide polymorphism Ser128Arg in the E-selectin
gene is associated with enhanced coagulation during human endotox-
emia. Blood 2005;105:2380–3.
34. Marasini B, Casari S, Zeni S, Turri O, Biondi M. E-selectin polymor-
phism in autoiimune diseases. Arthritis Rheum 1999;42:S324.
35. Rao R, Clarke J, Ortlepp S, Robinson M, Landis R, Haskard D. The
S128R polymorphism of E-selectin mediates neuraminidase-resistant
tethering of myeloid cells under shear flow. Eur J Immunol 2002;
32:251–60.
36. Nicum S, Midgley R, Kerr D. Colorectal cancer. Acta Oncol 2003;
42:263–75.
534 ALESSANDRO ET AL.
37. Houlston R, Tomlinson I. Polymorphisms and colorectal tumor risk.
Gastroenterology 2001;121:282–301.
38. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M,
Kannagi R. Contribution of carbohydrate antigens sialyl Lewis A and
sialyl Lewis X to adhesion of human cancer cells to vascular endothe-
lium. Cancer Res 1993;53:354–61.
39. Sawada R, Tsuboi S, Fukuda M. Differential E-selectin-dependent ad-
hesion efficiency in sublines of a human colon cancer exhibiting dis-
tinct metastatic potentials. J Biol Chem 1994;269:1425–3141.
40. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ.
Intravascular origin of metastasis from the proliferation of endothelium-
attached tumor cells: a newmodel for metastasis. Nat Med 2000;6:100–2.
41. Wong C, Song C, Grimes M, Fu W, Dewhirst M, Muschel R, Al-
Mehdi A. Intravascular location of breast cancer cells after spontane-
ous metastasis to the lung. Am J Pathol 2002;161:749–53.
42. Wells A. Tumor invasion: role of growth factor-induced cell motility.
Adv Cancer Res 2000;78:31–101.
43. Morbidelli L, Brogelli L, Granger HJ, Ziche M. Endothelial cell
migration is induced by soluble P-selectin. Life Sci 1998;62:7–11.
44. Laferriere J, Houle F, Huot J. Adhesion of HT-29 colon carcinoma
cells to endothelial cells requires sequential events involving E-selec-
tin and integrin beta4. Clin Exp Metastasis 2004;21:257–64.
45. Ye C, Kiriyama K, Mistuoka C, Kannagi R, Ito K, Watanabe T,
Kondo K, Akiyama S, Takagi H. Expression of E-selectin on endothe-
lial cells of small veins in human colorectal cancer. Int J Cancer
1995;61:455–60.
46. Sheen-Chen S, Eng H, Huang C, Chen W. Serum levels of soluble E-
selectin in women with breast cancer. Br J Surg 2004;91:1578–81.
47. Hu Y, Szente B, Kiely J, Gimbrone MJ. Molecular events in trans-
membrane signaling via E-selectin. SHP2 association, adaptor protein
complex formation and ERK1/2 activation. J Biol Chem 2001;276:
48549–53.
48. Cuvelier S, Paul S, Shariat N, Colarusso P, Patel K. Eosinophil ad-
hesion under flow conditions activates mechanosensitive signaling
pathways in human endothelial cells. J Exp Med 2005;202:865–
76.
49. Kumar P, Amin M, Harlow L, Polverini P, Koch A. Src and phospha-
tidylinositol 3-kinase mediate soluble E-selectin-induced angiogene-
sis. Blood 2003;101:3960–8.
50. Laferriere J, Houle F, Taher M, Valerie K, Huot J. Transendothelial
migration of colon carcinoma cells requires expression of E-selectin
by endothelial cells and activation of stress-activated protein kinase-
2 (SAPK2/p38) in the tumor cells. J Biol Chem 2001;276:33762–
72.
535E-SELECTIN POLYMORPHISMS AND METASTASIS FORMATION
